THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE
New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin (dabigatran), today are increasingly replacing warfarin and other indirect anticoagulants in preventing stroke in patients with non-valvular atrial fibrillation. They were superior to warfarin for some indi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-05-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1240 |
| _version_ | 1797232198615564288 |
|---|---|
| author | S. V. Moiseev |
| author_facet | S. V. Moiseev |
| author_sort | S. V. Moiseev |
| collection | DOAJ |
| description | New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin (dabigatran), today are increasingly replacing warfarin and other indirect anticoagulants in preventing stroke in patients with non-valvular atrial fibrillation. They were superior to warfarin for some indicators of efficacy and safety in randomized controlled trials. However, the experience of their study in real clinical practice is limited. The need in prospective, observational studies is dictated by the fact that usual practice differs from the conditions of the randomized clinical trials that may improve the efficiency and safety of the treatment, including the expense of strict criteria for patient selection, regular visits, constant safety monitoring and etc. The results of prospective observational XANTUS study and retrospective cohort studies that shown similar results of treatment with new oral anticoagulants in randomized clinical trials and routine clinical practice are presented in the review. |
| first_indexed | 2024-03-08T14:02:41Z |
| format | Article |
| id | doaj.art-0988eb4ae9c14b749246a1d318e4ebf0 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:56:28Z |
| publishDate | 2016-05-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-0988eb4ae9c14b749246a1d318e4ebf02024-04-01T07:43:33ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-05-0112222022610.20996/1819-6446-2016-12-2-220-2261207THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICES. V. Moiseev0I.M. Sechenov First Moscow State Medical University, Moscow; M.V. Lomonosov Moscow State University , MoscowNew oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin (dabigatran), today are increasingly replacing warfarin and other indirect anticoagulants in preventing stroke in patients with non-valvular atrial fibrillation. They were superior to warfarin for some indicators of efficacy and safety in randomized controlled trials. However, the experience of their study in real clinical practice is limited. The need in prospective, observational studies is dictated by the fact that usual practice differs from the conditions of the randomized clinical trials that may improve the efficiency and safety of the treatment, including the expense of strict criteria for patient selection, regular visits, constant safety monitoring and etc. The results of prospective observational XANTUS study and retrospective cohort studies that shown similar results of treatment with new oral anticoagulants in randomized clinical trials and routine clinical practice are presented in the review.https://www.rpcardio.online/jour/article/view/1240atrial fibrillationstrokea new oral anticoagulantrivaroxabandabigatran |
| spellingShingle | S. V. Moiseev THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE Рациональная фармакотерапия в кардиологии atrial fibrillation stroke a new oral anticoagulant rivaroxaban dabigatran |
| title | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE |
| title_full | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE |
| title_fullStr | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE |
| title_full_unstemmed | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE |
| title_short | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE |
| title_sort | efficacy and safety of new oral anticoagulants in patients with atrial fibrillation in clinical practice |
| topic | atrial fibrillation stroke a new oral anticoagulant rivaroxaban dabigatran |
| url | https://www.rpcardio.online/jour/article/view/1240 |
| work_keys_str_mv | AT svmoiseev theefficacyandsafetyofneworalanticoagulantsinpatientswithatrialfibrillationinclinicalpractice AT svmoiseev efficacyandsafetyofneworalanticoagulantsinpatientswithatrialfibrillationinclinicalpractice |